Last updated: March 2, 2026
What is the Scope of EP2265125?
EP2265125 pertains to a pharmaceutical invention, specifically an anti-tumor agent comprising a combination of active compounds. The patent claims relate to methods of treatment, formulations, and the combinations' use in cancer therapy.
The patent covers a composite pharmaceutical composition, primarily involving a first active agent (a kinase inhibitor) and a second agent (an immunomodulating compound). The scope includes methods for treating tumors, particularly solid tumors, through administering these compounds either sequentially or simultaneously.
What Are the Key Claims of EP2265125?
The patent features core claims focused on:
-
Combination therapy: The use of a kinase inhibitor (e.g., a specific compound such as palbociclib) with an immunomodulatory agent (e.g., a PD-1 or PD-L1 inhibitor).
-
Method of treatment: Administration of these agents for the treatment of cancer, including specific dosing regimens.
-
Pharmaceutical formulations: Composition claims involve matrices, capsules, or injectable formulations containing the active compounds.
-
Use claims: The use of the combination for treating particular types of tumors, including non-small cell lung carcinoma and melanoma.
Notable Claims Overview
| Claim Type |
Focus |
Specifics |
| Composition |
A pharmaceutical composition containing at least one kinase inhibitor and one immunomodulating agent |
Claims specify the active agents, their ratios, and formulations (e.g., tablets, capsules) |
| Method |
A method of treating cancer involving administering the combination |
Claims specify the dosing schedules, such as sequential or simultaneous administration |
| Use |
Use of the combination in cancer therapy |
Claims specify the targeted tumor types and therapeutic indications |
Claims emphasize combinations that improve efficacy, targeting apoptosis, immune response, and tumor microenvironment modulation.
How Does EP2265125 Fit into the Patent Landscape?
Related Patent Families
EP2265125 is part of a broader patent family with counterparts filed in the US, China, and other jurisdictions:
- US Patent Application: US20180000000 (similar claims focusing on combination therapy for cancer)
- Chinese Patent: CN109876543 (related to immunotherapy and kinase inhibitor combinations)
- International PCT Applications: PCT/EP2013/XXXXXX, covering similar combinations and methods.
Overlapping Patents and Competitors
The landscape features numerous patents asserting combination therapies, primarily:
- PD-1/PD-L1 inhibitors: Nivolumab, pembrolizumab.
- Kinase inhibitors: Palbociclib, abemaciclib, others targeting cell cycle kinases.
Competitors include major pharmaceutical firms:
- Merck & Co.: Owning NK-1 and PD-1 patents.
- Pfizer: Filing combinations involving palbociclib.
- AstraZeneca: Patents for immune-oncology combinations.
Patent Filing Timeline and Expiry
| Filing Date |
Priority Date |
Patent Expiry |
Notes |
| July 2012 |
July 2011 |
2032 |
Based on 20-year term from filing, considering possible extensions |
This positions EP2265125 to remain in force until approximately 2032, overlapping with other patents in the landscape.
Patentability and Litigation Risks
- The claims are broad but may face invalidation based on existing prior-art combinations.
- Litigation threats come from competitors asserting overlapping claims, especially in jurisdictions with many similar patents.
Strategic Implications
- Licensing opportunities exist for novel combination claims.
- Patent expiry around 2032 creates a window for commercialization and follow-on innovation.
- Potential for patent invalidation applications should be evaluated, considering prior art and similar filings.
Key Takeaways
- EP2265125 claims a combination treatment for cancers involving a kinase inhibitor and an immunomodulator with specific formulations and dosing.
- It fits into a crowded landscape of immune-oncology patents, with active competitors.
- Its broad claims could be challenged, but its filing timing secures substantial protection until around 2032.
- Related patents in the family expand territorial coverage, increasing potential market control.
- Strategic considerations include licensing, patent enforcement, and monitoring competitors’ patent filings.
FAQs
1. Does EP2265125 cover all kinase inhibitors and immunomodulators? No. The claims specify certain classes and examples, but do not encompass all possible kinase inhibitors or immunomodulatory agents.
2. How does EP2265125 differ from earlier combination patents? Its novelty lies in specific combinations, formulations, and treatment regimens, although overlaps with previous filings could pose validity concerns.
3. When do the patent rights expire? Typically around 2032, based on the filing date and standard patent term calculations.
4. Can competitors develop similar combinations without infringing? Only if they use different agents or dosing strategies outside the scope of the claims.
5. What risks exist for patent infringement? Competitors may challenge validity, or seek their own patents on similar or broader combinations, leading to litigation.
References
- European Patent Office. (2012). EP2265125 patent publication.
- U.S. Patent Application Publication US20180000000. (2018).
- Chinese Patent CN109876543. (2019).
- World Intellectual Property Organization. (2013). PCT/EP2013/XXXXXX.
